about
Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers.Typologies of prescription opioid use in a large sample of adults assessed for substance abuse treatmentShortening the Current Opioid Misuse Measure via computer-based testing: a retrospective proof-of-concept study.Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.Gender differences in risk factors for aberrant prescription opioid useGeographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse.Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy.Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM)Feasibility of tablet computer screening for opioid abuse in the emergency departmentRetrospective accounts of initial subjective effects of opioids in patients treated for pain who do or do not develop opioid addiction: a pilot case-control studyAbuse risks and routes of administration of different prescription opioid compounds and formulations.Development and validation of the Current Opioid Misuse MeasureValidation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).Validation of the Spanish Addiction Severity Index Multimedia Version (S-ASI-MV).Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients?Can abuse deterrent formulations make a difference? Expectation and speculation.Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database.Cross-Validation of a Screener to Predict Opioid Misuse in Chronic Pain Patients (SOAPP-R).The effect of computer-mediated administration on self-disclosure of problems on the addiction severity indexElectronic opioid risk assessment program for chronic pain patients: barriers and benefits of implementation.Measuring online endorsement of prescription opioids abuse: an integrative methodology.Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain.Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP).Validation of a screener and opioid assessment measure for patients with chronic pain.Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.Internet-based survey of nonmedical prescription opioid use in the United States.National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.Internet surveillance: content analysis and monitoring of product-specific internet prescription opioid abuse-related postings.Spanish translation and linguistic validation of the screener and opioid assessment for patients with pain-revised (SOAPP-R).Associations between public health indicators and injecting prescription opioids by prescription opioid abusers in substance abuse treatment.Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.Illustration of a statistical process control approach to regional prescription opioid abuse surveillance.Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: early findings from the NAVIPPRO surveillance system.Measuring attractiveness for abuse of prescription opioids.Addiction severity assessment tool: development of a self-report measure for clients in substance abuse treatment.Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49: A National Internet Survey.Development and preliminary experience with an ease of extractability rating system for prescription opioids.Food, mood, and attitude: reducing risk for eating disorders in college women.Assessing abuse potential of new analgesic medications following market release: an evaluation of Internet discussion of tapentadol abuse.
P50
Q25256775-CEEB4B57-29D7-4CF5-8F4C-AC6EEA6518A9Q28743202-DC780C1F-379F-48D6-B266-AB862F6D4F22Q33592817-45FD8594-526F-460F-98EC-0D81223FD936Q33633386-D812D001-DAA6-4598-856F-C2418FA3A7F1Q33761976-542CBBB8-9A73-4BE4-84AB-2ADBBDD43CB4Q34158623-35361000-E291-4779-B71D-3462F2170CCBQ34204266-1EB135EA-BB5F-4A5D-BAC3-ECC52DBF01D6Q34521652-3702DBD3-101E-40E9-B886-08393475628EQ35017909-9F097158-959C-4BF6-87C5-63E0C89164B8Q35156524-61459172-B78D-4172-BD09-8BC728C9DB23Q35541054-F8F9D66E-99EE-4738-9F82-CF037CFA0B84Q35944701-F31FE64C-E728-4684-87CD-A76045D67C12Q36609198-B3ED3169-5E68-410A-AA42-95FEC79E140DQ37118446-4F4F1B63-1A5C-4704-94FC-D32C788F632EQ37148221-1B5F3177-A8CE-44FF-B95D-C899549D1902Q37223480-6FAD4805-E348-48E9-9B9A-8967F1E991C9Q37227555-407080F9-65B8-4B09-983A-00D36625F3AFQ37266027-13062B52-CEFD-4798-A7DE-20A3304771A0Q37478365-71FA47EC-D268-4BCD-BE21-B3ECD242939DQ38166451-3915C24A-79DF-48DD-8658-9E26B86890B0Q39589058-B71515D9-FFD1-4C58-AA93-FB51E0F2B2ABQ40221100-722040BF-295D-44D3-AA3C-593BF4ED1893Q40293198-FF4DAEEB-E6D3-428A-8BD8-AAC406735CECQ40474521-6DA9773F-73CB-4905-BCB8-E7792D76FE4FQ43225439-EB498043-3D27-4D69-8E28-36ECB277786EQ44103081-4895BE5A-0BA1-4561-B23B-1351B7A87F6CQ44335315-ADC2C9DC-993E-43D4-BF27-E84CCBB03CDCQ44336013-FA23AD4B-8DE5-4170-AF02-464EA08A4E00Q44338972-A77E7B8A-27B1-4992-AEFE-7BF8F4636BDFQ44339577-BC7C95B3-1E25-406D-ACAE-08D29670EC8FQ44342495-A1BE882D-5D63-430F-86EC-67182BD9BCAEQ44351702-E21597BA-EE3F-4086-9772-AD7231374EEFQ45887814-B4D36467-4145-4E97-907F-B782B1DB7294Q46156587-7B069EFE-56B1-422D-8B46-0EB00789C4E7Q46580354-E9DCDC58-12D3-4130-9564-7CD15FE8E333Q46716773-FD7888FB-152F-4E7D-B726-DA36FDE8C85BQ48204458-69182186-EC97-489E-A2BA-D6D40F8C4634Q48674921-900A436A-3B85-4E06-A0EB-3740A92AA00DQ50747894-589F0AAE-768E-4D48-B4B5-1EB93B0410D8Q51455918-B11624BE-AB57-4E42-A6F5-B2235BF4F0E1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stephen F. Butler
@ast
Stephen F. Butler
@en
Stephen F. Butler
@es
Stephen F. Butler
@nl
Stephen F. Butler
@sl
type
label
Stephen F. Butler
@ast
Stephen F. Butler
@en
Stephen F. Butler
@es
Stephen F. Butler
@nl
Stephen F. Butler
@sl
altLabel
S F Butler
@en
Stephen F Butler
@en
prefLabel
Stephen F. Butler
@ast
Stephen F. Butler
@en
Stephen F. Butler
@es
Stephen F. Butler
@nl
Stephen F. Butler
@sl
P106
P1153
7202738163
P21
P31
P496
0000-0002-6132-5883